Pharmacist knowledge of gout management: impact of an educational intervention
- PMID: 35599318
- PMCID: PMC9125937
- DOI: 10.1186/s41927-022-00259-x
Pharmacist knowledge of gout management: impact of an educational intervention
Abstract
Background: Pharmacists play a key role in community gout education. We investigated pharmacist knowledge of gout management and developed an educational intervention which was assessed in a cohort of Irish pharmacists.
Methods: A ten-question questionnaire about gout management was developed to assess pharmacists' knowledge. A 14 min 26 s video educational intervention was co-designed by a rheumatologist, a pharmacist, and designer of pharmacy education resources. The effectiveness of this pharmacy-specific intervention was assessed using the same questionnaire in 53 pharmacists (25 in the intervention group; 28 in the control group). Contingency tables were used to analyse differences between groups.
Results: There were 173 pharmacist respondents to the initial survey; 35.3% answered that first-line therapy for gout involves a combination of a xanthine oxidase inhibitor (e.g., allopurinol) combined with a prophylactic agent (e.g., colchicine), and 28.9% of respondents answered that colchicine prophylaxis should be used when initiating urate-lowering therapy. Following the educational intervention, pharmacist's knowledge about gout management increased across many domains, including serum urate targets when using urate-lowering therapy (p = 0.006), use of colchicine prophylaxis (p = 0.011), and duration of colchicine use (p < 0.001).
Conclusion: Gout management recommendations can be impeded if translation into pharmacy practice is neglected. Pharmacists are a valuable information resource for patients. Co-designing a brief education intervention with pharmacists is an effective, low-cost way to increase pharmacist knowledge on the management of gout.
Keywords: Crystal arthritis; Education; Gout; Multi-disciplinary care.
© 2022. The Author(s).
Conflict of interest statement
Authors ED, MK and GM have no competing interests to declare. Author ND received consulting fees not related to the work within this manuscript from AstraZeneca, Horizon Dyve Biosciences, PK Med, JW Pharmaceuticals, Selecta, Arthrosi and Cello Health; and grants or contracts from AstraZeneca and Amgen within the last 36 months.
Similar articles
-
Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.Contemp Clin Trials. 2016 Sep;50:106-15. doi: 10.1016/j.cct.2016.07.019. Epub 2016 Jul 20. Contemp Clin Trials. 2016. PMID: 27449546 Free PMC article. Clinical Trial.
-
Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.Am J Med. 2019 Mar;132(3):354-361. doi: 10.1016/j.amjmed.2018.11.011. Epub 2018 Nov 29. Am J Med. 2019. PMID: 30503879 Free PMC article. Clinical Trial.
-
Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database.Int J Rheum Dis. 2023 Sep;26(9):1770-1778. doi: 10.1111/1756-185X.14825. Epub 2023 Jul 10. Int J Rheum Dis. 2023. PMID: 37431263
-
Management of acute and chronic gouty arthritis: present state-of-the-art.Drugs. 2004;64(21):2399-416. doi: 10.2165/00003495-200464210-00003. Drugs. 2004. PMID: 15481999 Review.
-
How Can We Improve Disease Education in People with Gout?Curr Rheumatol Rep. 2018 Mar 8;20(3):12. doi: 10.1007/s11926-018-0720-x. Curr Rheumatol Rep. 2018. PMID: 29516200 Free PMC article. Review.
References
Grants and funding
LinkOut - more resources
Full Text Sources